Photo from wikipedia
www.newoncology.de Background: The use of immune checkpoint inhibitors has shown promise in lung cancer as well as several other tumor types. However, two of their limitations are the overall relatively… Click to show full abstract
www.newoncology.de Background: The use of immune checkpoint inhibitors has shown promise in lung cancer as well as several other tumor types. However, two of their limitations are the overall relatively low response rate as well as the lack of powerful predictors for response. Recently, several studies have shown that stratification of patients according to the load of somatic mutations can provide predicitive information for either ‘mono’ or ‘combinational’ immunotherapy. Here, we describe the use of a hybrid-capture based next-generation sequencing assay, NEOplus, to determine the somatic mutational load in clinical samples.
Journal Title: Journal of Thoracic Oncology
Year Published: 2017
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!